首页>投融资
Sibylla Biotech
A轮
Sibylla Biotech SRL is a developer of patent-based software designed to apply algorithms and drug design protocols. The company's software focuses on drug discovery protocols based on original reaction path sampling and data reduction algorithms to avoid folding and thus bring the protein to degradation, enabling medical practitioners with ways in rational drug discovery research for the treatment of incurable diseases.In October 2022, Sibylla Biotech closed its €23 million Series A financing round
基本信息
-
公司全称Sibylla Biotech SPA
-
类型生物技术研究商
-
产业领域软件/互联网技术服务、药品研发/制造
-
公司人数不明确
-
地址Salita dei Molini, 2 TRENTO TRENTO 38123; IT;
-
联系电话39 347 650 3353
-
邮箱ontact@sibyllabiotech.it
-
成立时间2008-04-01
投融资
-
2022-10-04A轮2300万欧元Indaco Venture PartnersSeroba Life SciencesV-BIO VenturesClaris VenturesVI PartnersCDP Venture CapitalEvolution Fund3B Future Health Fund
相关投融资企业
A轮(A2)
Inato自动执行数据结构和分析，交叉检查数据源并提供有关此数据的见解。Inato的AI驱动平台具有用于收集和分析临床试验中使用的数据的工具，可帮助制药公司大幅降低药物开发成本。通过加速临床试验，Inato帮助新疗法以更低的价格更快地送达患者。
A轮(A2)
Trailhead Biosystems率先使用机器学习和生物信息学开发基于细胞的疗法。Trailhead的高维实验设计（HD-DoE）平台将发育生物学和细胞疗法与先进的机器人技术、计算机化的实验设计和分析相结合，以在细胞疗法的开发中执行特定于过程的参数优化。
Trailhead Biosystems已经开发了一个专有平台，用于执行系统级的复杂生物学问题的研究，范围从生成针对专业人类细胞的工业规模制造条件到在癌症和抗病毒疗法中的组合药物发现。Trailhead通过机器学习来发现关键的过程参数和解释生物学反应的组合输入，从而自动进行生物学上规模最大的实验。Trailhead的突破性方法完全不同于标准假设驱动研究的有限探索力。
A轮
Sibylla Biotech SRL is a developer of patent-based software designed to apply algorithms and drug design protocols. The company's software focuses on drug discovery protocols based on original reaction path sampling and data reduction algorithms to avoid folding and thus bring the protein to degradation, enabling medical practitioners with ways in rational drug discovery research for the treatment of incurable diseases.In October 2022, Sibylla Biotech closed its €23 million Series A financing round
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息